pfizer netherlands

What pfizer netherlands does

Pfizer Netherlands is the Dutch operating subsidiary (Pfizer bv) of Pfizer Inc., the global pharmaceutical company listed on the New York Stock Exchange under ticker PFE. The entity is incorporated in the Netherlands as a private limited company (BV) with its headquarters at Rivium Westlaan 142 in Capelle aan den IJssel, and it wholly owns three Dutch operating subsidiaries: Pfizer Export BV, PF Asia Manufacturing BV, and PF Consumer Health BV. The company discovers, develops, and supplies medicines and vaccines across five therapeutic areas — oncology, infectious diseases, inflammatory diseases, rare diseases, and vaccines — with key products including Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 antiviral), and the pneumococcal conjugate vaccine (PCV). It operates as a distribution, regulatory, and professional-engagement hub within Pfizer Inc.'s global network, distributing products in the Netherlands and participating in international programs such as the Gavi partnership, through which the 1 billionth PCV dose was delivered to Ethiopia in October 2024.

The company serves three principal customer groups: patients (with more than 1.3 billion people using a Pfizer medicine or vaccine globally in 2022), healthcare professionals (served via the PfizerPro portal at pfizerpro.nl and a free 0800-MEDINFO medical information line), and government and international health authorities (via national immunization programs and partnerships such as Gavi and the Accord for a Healthier World covering 45 low-income countries). Its go-to-market is enterprise field sales targeting prescribers, hospitals, pharmacies, and government health bodies, with adverse-event reporting infrastructure that submits safety data to the Dutch Medicines Evaluation Board (CBG), the FDA, and European regulators within seven to fifteen days depending on severity. The entity is governed by Dutch law and operates within the regulatory frameworks of the EMA, FDA, and CBG, with 175 years of Pfizer heritage (since 1849) and billions in annual group-level R&D investment underpinning its drug safety and pharmacovigilance capabilities.

Name

pfizer netherlands

Legal name

Pfizer bv

Website

https://pfizer.nl

Company type

Public

Founded year

1849

Operating status

Operating

Short description

Pfizer Netherlands is the Dutch operating subsidiary (Pfizer bv) of Pfizer Inc. It distributes and supplies medicines and vaccines across oncology, infectious diseases, inflammatory diseases, rare diseases, and vaccines, serving Dutch patients, healthcare professionals, and government health authorities.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Prescription pharmaceuticals
• Vaccine development
• Oncology medicines
• Rare disease treatments
• Infectious disease therapy

Headquarters

HQ city

Capelle aan den IJssel

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Medicines: Pfizer discovers, develops, and delivers prescription medicines for cancer, infectious diseases, inflammatory diseases, and rare diseases. Revenue is generated through product sales to healthcare providers, hospitals, and pharmacies. The company operates globally with products distributed through multiple channels including national health systems.
2. Vaccines: Pfizer develops and manufactures vaccines including pneumococcal conjugate vaccines. More than 50% of Pfizer's pneumococcal vaccine production supports access in low- and lower-middle-income countries on a non-profit basis through Gavi partnerships. Commercial vaccine sales generate revenue in developed markets.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Pfizer Netherlands discovers, develops, and supplies prescription medicines and vaccines across multiple therapeutic areas, including oncology, infectious diseases, inflammatory diseases, rare diseases, and preventive vaccination. As the Dutch subsidiary of Pfizer Inc., it distributes flagship products such as Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 antiviral), and the pneumococcal conjugate vaccine to healthcare providers, pharmacies, and national immunization programs in the Netherlands and through global access partnerships.

Product overview

Pfizer Netherlands operates as part of the global Pfizer pharmaceutical company, offering a portfolio of medicines and vaccines. Key products include Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 antiviral), and pneumococcal conjugate vaccines. The company focuses on therapeutic areas including cancer, infectious diseases, inflammatory diseases, rare diseases, and vaccines. Pfizer serves healthcare professionals through the PfizerPro portal and provides medicines and vaccines to patients in the Netherlands.

Differentiator

Problem solved

Functional benefit

Products and services

• Comirnaty (COVID-19 vaccine)

Quantifiable outcome

• 1 billion+ pneumococcal vaccine doses delivered
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• Accord for a Healthier WorldcoreStrategic or Co-development Partner · 1 January 2022Pfizer's Accord for a Healthier World initiative aims to expand access in 45 low-income countries to all medicines and vaccines for which Pfizer has global rights, on a non-profit basis. The initiative is designed to provide 1.2 billion people in low-income countries access to Pfizer's full portfolio without profit motive, while also working with governments to address system-level barriers that prevent access.
• Gavi, The Vaccine AllianceflagshipStrategic or Co-development Partner · 1 January 2009Pfizer has delivered its 1 billionth pneumococcal conjugate vaccine via its partnership with Gavi, The Vaccine Alliance. Since 2010, Pfizer has supplied pneumococcal vaccines to 57 countries eligible for Gavi support, helping protect an estimated 300+ million children. More than 50% of Pfizer's pneumococcal vaccine production supports access in low- and lower-middle-income countries on a non-profit basis. The partnership includes the Pneumococcal Advance Market Commitment (AMC), a public-private financing mechanism designed to create a sustainable market, enable development and manufacturing investments, and provide affordable and stable vaccine supply at heavily subsidized prices for children in Gavi-eligible countries.
• TEDxEindhovenminorGTM or Marketing PartnerPfizer partners with TEDxEindhoven to host events that challenge people to think about future healthcare. The collaboration aims to stimulate discussion and innovative thinking about healthcare challenges.
• Talent for CareminorStrategic or Co-development PartnerPfizer and Talent for Care share the same goal: striving for better patient care. The partnership involves investing in young organizational talent and developing a comprehensive and personalized leadership development program.
• College ter Beoordeling van Geneesmiddelen (CBG)coreStrategic or Co-development PartnerPfizer collaborates with the Dutch Medicines Evaluation Board (CBG) for drug safety monitoring. Safety data from original reports and analysis are submitted to the CBG for review. Adverse event reports are also submitted to FDA and European authorities as required by law.
• FDA and European Regulatory AuthoritiescoreStrategic or Co-development PartnerPfizer collaborates with regulatory authorities worldwide including FDA and European authorities for drug safety monitoring. The company submits safety reports within seven days for unexpected life-threatening adverse events or deaths, and within fifteen days for serious (un)expected possible adverse events.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Bayer Netherlands (Pharmaceuticals): Dutch pharmaceutical operations of a broader life sciences conglomerate with overlapping women's health, cardiovascular, and specialty pharma franchises. Comparable in scale and channel mix, though broader consumer and crop science exposure makes it a wider incumbent rather than a pure-play peer.

Direct peers

• Johnson & Johnson Innovative Medicine Netherlands: Dutch pharmaceutical subsidiary of J&J with overlapping therapy areas (oncology, immunology, infectious disease) and a comparable HCP- and hospital-focused go-to-market. Direct peer in regulatory, access, and pricing dynamics in the Netherlands.
• MSD (Merck) Netherlands: Dutch subsidiary of a global pharmaceutical company with a similar prescription-medicine and vaccine portfolio (notably HPV vaccine Gardasil) sold through the same HCP channel and national immunization programs. Directly comparable in therapeutic breadth, regulatory profile, and Dutch GTM model.
• Bristol-Myers Squibb Netherlands: Dutch subsidiary of a global oncology and specialty pharma competing in similar hospital and specialty channels. Comparable in HCP engagement model and post-approval safety commitments in the Dutch market.
• GSK Netherlands: Dutch operations of a global vaccine and specialty medicines leader; competes head-to-head with Pfizer in pneumococcal, meningococcal, and adult immunization markets. Closest direct peer in the vaccines franchise that is core to Pfizer Netherlands' Gavi-driven volume.
• Eli Lilly Netherlands: Dutch affiliate of a major US-headquartered biopharma with overlapping therapeutic areas (oncology, immunology, diabetes) and a similar HCP-led distribution and access strategy in the Netherlands.
• Roche Netherlands: Dutch arm of a global biopharmaceutical company with strong oncology and diagnostics franchises, distributed through the same hospital and specialist channels. Highly comparable in portfolio mix, regulatory intensity, and enterprise sales motion.
• Novartis Netherlands: Subsidiary of a major Swiss pharma with overlapping therapeutic areas (oncology, cardiovascular, immunology) and a similar prescription-medicine, HCP-driven distribution model in the Netherlands. Comparable in scale, regulatory exposure, and patient access programs.
• AstraZeneca Netherlands: Dutch affiliate of a global biopharmaceutical company with strong oncology, respiratory, and vaccines portfolios. Overlaps with Pfizer in hospital-administered specialty drugs and enterprise HCP sales motion.
• Sanofi Netherlands: Dutch subsidiary of a major vaccines and specialty care player competing with Pfizer in pediatric and adult immunization. Comparable in scale, regulatory exposure, and dependence on national immunization programs for volume.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pfizer netherlands